Tirzepatide to Slow Biological Aging (NCT07220473) | Clinical Trial Compass
RecruitingPhase 2
Tirzepatide to Slow Biological Aging
United States90 participantsStarted 2026-02-27
Plain-language summary
This pilot clinical study aims to investigate the potential effects of tirzepatide on biological aging in older adults. In this novel study, 90 adults aged 55-70 years with an indication for tirzepatide weight-loss therapy will be randomized to receive either tirzepatide 2.5 mg subcutaneously (SC) weekly or no drug for 24 weeks, followed by 12 weeks off the drug. Since tirzepatide is already recognized as a highly effective weight-loss agent in this population, the primary focus will not be on measuring weight loss. Instead, the study will document the effects of tirzepatide on markers of aging, physical function, and overall health.
Who can participate
Age range55 Years – 70 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age 55-70 years
✓. BMI ≥ 30 kg/m² or ≥ 27 kg/m² if also with ≥ 1 weight-related comorbidity
✓. If taking anti-inflammatory or blood-pressure-/lipid-/glucose-lowering medications, no change in dose for ≥12 weeks prior to entry and no plans to dose escalate for the study duration
✓. Willing and able to provide written informed consent and undergo all required study procedures
Exclusion criteria
✕. BMI \>35 kg/m²
✕. Uncontrolled or end-stage, comorbid, cardiometabolic disease, in the opinion of the site investigator
✕. Significant neurocognitive impairment, in the opinion of the site investigator
✕. Current or planned use of medications for the treatment of obesity, or medications likely to cause significant changes in weight, during the study period (see prohibited medications, section 6.0)
✕. Use of insulin
What they're measuring
1
Change in DNA Methylation-Based Biological Age
Timeframe: Immediately before and after the study visit at Weeks 4, 12, and 24
Trial details
NCT IDNCT07220473
SponsorThe University of Texas Medical Branch, Galveston
✕. Plans to newly engage in formal, intensive physical activity or diet (such as ketogenic or very low carbohydrate) programs during the study period
✕. Active eating disorder
✕. Use of human growth hormone, tesamorelin, supraphysiologic testosterone or estradiol (stable doses for contraception, hypogonadism or other indications for exogenous sex steroid replacement therapy permitted) or anabolic steroids \<12 W prior to entry, unless on a stable dose for \>24 W prior to entry, or plans to start any of these medications while on study